Webinars

Speaker:  Patrick M Dougherty, Professor of Pain Medicine | MD Anderson Cancer Center

Take an in-depth look at Dr. Dougherty’s innovative research into neuropathic pain experienced by cancer patients.

For 22 years, Dr. Dougherty has held appointment as Professor of Pain Medicine at the University of Texas M.D. Anderson Cancer Center. His recent work centers on determining the mechanisms of neuropathic pain experienced by cancer patients. The work has been composed of parallel studies conducted in both humans and animals. In the human studies, he and his team have conducted psychophysical studies to define the sensory fibers involved in these pain conditions; and more recently, expanded this work to utilize human dorsal root ganglia tissue excised during surgical treatment for cancer. The animal studies have been to define both the peripheral and central neurophysiological mechanisms that are altered following cancer and cancer chemotherapy and to determine agents that may provide a neuroprotective role. The current emphasis in each of these studies is to determine the role that innate immune mechanisms play in the pathogenesis of cancer- and cancer treatment-evoked neuropathic pain.

*All times are Eastern Time Zone

Speaker:  J. Lowry Curley, PhD, Co-Founder and CEO of AxoSim

Take an in-depth look at AxoSim’s case study on chemotherapeutic drug induced peripheral neuropathy and how this research is leading to the development of AxoSim’s NerveSim® 2.0 platform.

AxoSim assessed NerveSim’s ability to screen for implications of functional and structural nerve dysfunction in chemotherapy-induced peripheral neuropathy. First, this research demonstrates that NerveSim accurately recreates axonal growth, orientation, and function analogous to mature nerve anatomy. By screening known neurotoxic compounds, AxoSim established the potential for its model to prove not only whether a drug is toxic, but to also provide insights into the mechanism of that toxicity. It’s the first 3D in vitro model to collect electrophysiological and histomorphic metrics to assess in vivo pathophysiology.

*All times are Eastern Time Zone

Speaker: Thomas Hartung, MD, PhD, Consulting VP of Scientific Affairs at AxoSim and Professor and Chair, Johns Hopkins University

Neurological impairments are usually irreversible because of limited regeneration in the central nervous system. The regenerative capacity of stem cells makes them an attractive candidate for transplantation therapies, with many stem cells showing promise in basic research and preclinical trials.

Learn about how advances in iPSC-derived organoid models recapitulate the “real” brain environment for CNS precision medicine.

Speaker: Anup Sharma, PhD, Lead Scientist at AxoSim

Learn about the use of Human Schwann Cells in preclinical peripheral neuropathy research. In this webinar, Dr. Sharma presents on our human peripheral neurotoxicity assay with Schwann Cells which recapitulates peripheral neuropathy in small molecules and antibody drug conjugates.